US 11512309
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
granted A61KA61K31/713A61K48/005
Quick answer
US patent 11512309 (Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/713, A61K48/005, A61P, A61P27/02